Board Search for a publicly traded company... is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing significant unmet medical needs and burden to society, patients, and their family. The company's current pipeline focuses on the central nervous system, respiratory, and metabolic diseases. They are using chemical genomics driven technology platforms and proprietary chemistry to develop new medicines.
The lead drug candidate, , is ready for continued clinical development for multiple neuropsychiatric indications. These include schizophrenia, bipolar disorder (BD), major depressive disorder (MDD), behavioral and psychotic symptoms, dementia or Alzheimer’s disease (BPSD), Parkinson’s disease psychosis (PDP), and attention deficit hyperactivity disorder (ADHD). Furthermore, RP5063 is also ready for clinical development for two respiratory indications — pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to RP5063 for the treatment of PAH in November 2016 and IPF in April 2018.
The leadership and management team is composed of highly successful and experienced professionals from the pharmaceutical industry and have a demonstrated track record of taking drugs through the development process to the global market.
We are searching for 2 board members. Searching for executives to sit on the board. They are a publicly-traded company looking for Executives to join their Board of Directors.